Politico | Coronavirus: FDA advisory panel recommends use of Pfizer vaccine
- Decision paves the way for the agency to authorise emergency use of the Covid-19 shot
- The vaccine from Pfizer and BioNTech is the first one to undergo FDA review
This story is published in a content partnership with POLITICO. It was originally reported by Sarah Owermohle and Zachary Brennan on politico.com on December 10, 2020.
An independent FDA advisory committee said that the benefits of Pfizer‘s coronavirus vaccine outweigh the risks, setting the stage for the agency to authorise emergency use of the shot for people 16 and older.
The panel – comprising academic scientists, doctors and officials from other federal health agencies – voted 17 to 4 in favour of the vaccine, with one member abstaining.
Developed by Pfizer’s German partner, BioNTech, the Covid-19 vaccine is the first to undergo FDA review. The vaccine proved 95 per cent effective at preventing disease in a 44,000-person US trial whose peer-reviewed results were published on Thursday in the New England Journal of Medicine.
01:55
Coronavirus vaccine: UK grandmother is first person outside trials to get Pfizer Covid-19 shot
Members of the FDA advisory committee supported authorising the vaccine but had questions about possible allergic reactions reported in Britain. Several of the experts also pushed unsuccessfully for the panel to endorse a narrower authorisation that would leave out some teens and population groups at lower risk from the virus.
The panel also debated when US clinical trial participants who got a placebo should get the real vaccine, and whether the vaccine could be given as one dose instead of two, after data published this week showed a swift immune response after a single jab.
The FDA’s top vaccine official, Peter Marks, has said that the agency could give the vaccine the green light within days, after an internal review concluded that the shot showed “a favourable safety profile, with no specific safety concerns”.
The Trump administration is ready to launch a massive vaccination campaign as early as Monday, which public health experts say is the country’s best bet to end a pandemic that has killed over 290,000 Americans and infected 15.5 million so far.
But there are still lingering questions about who should – and should not – get the vaccine.
UK says those with serious allergies shouldn’t get Pfizer virus vaccine
There are fresh concerns after reports from Britain this week that two health care workers with serious, known allergies had allergic reactions after handling the shots. Britain on Wednesday said that people with a “history of a significant allergic reaction” should not receive the Pfizer vaccine, which it authorised earlier this month.
“There are 10 of millions of people in [the United States] who carry EpiPens with them, because they have peanut allergies, because they have egg allergies, who are going to believe now that they can’t get this vaccine. That’s a lot of people,” said Paul Offit, a University of Pennsylvania vaccine expert on the committee.
“We need to drill down on those two people in the UK” and understand how severe the reaction could be, he added.
FDA on Thursday asked Pfizer and BioNTech to add anaphylaxis – or life-threatening allergic reactions – to the list of adverse reactions they would monitor post-authorisation as part of what is known as a pharmacovigilance plan.
The agency is also discussing warning labels and contraindications with Pfizer and may include a warning that the vaccine should not be administered to anyone with severe allergic reactions to any component of other vaccines, said Marion Gruber, director of FDA‘s Office of Vaccines Research and Review.
Offit suggested given the vaccine to people with known severe allergies in a carefully controlled trial to quickly understand the risks and assure the public that this is not a serious problem, “because this issue is not going to die until we have better data”. But he did not suggest FDA should not authorise the vaccine for the broader population in the meantime.
The agency also called for more data on the vaccine‘s safety and efficacy in teens, pregnant women and people with allergies, though that would not stall emergency authorisation. Pfizer is one of the only manufacturers studying its vaccine in children as young as 12 years old, but for now it is seeking permission to use the vaccine in people 16 years and older.
Younger people in Pfizer‘s clinical trial reported more adverse reactions, and more severe ones, to the vaccine, than did older trial volunteers, said Susan Wollersheim, a medical officer in FDA’s biologics department. But overall reactions to the vaccine were relatively mild and included injection site pain, headaches or fever a day after inoculation.
US data confirms Pfizer vaccine is strongly protective against Covid-19
The FDA advisory committee also explored the thorny question of when trial volunteers who got a placebo could receive the working vaccine.
Pfizer had pushed FDA for permission to give the vaccine to members of its trial‘s placebo group immediately after authorisation. The plan that caused tension with the agency, because it would effectively end the randomised, controlled study without gathering enough data to answer questions about the vaccine’s long-term safety and the duration of the protection it provides.
Now Pfizer has proposed following participants for six months after their second shot before those in the placebo group can get the vaccine.
Advisory panel members at Thursday‘s meeting suggested an alternative plan where placebo patients in the Pfizer trial could be first to receive the vaccine within their own priority group – such as essential workers or the elderly. That would ensure they would not push ahead of people at greater risk from the virus, but would still have an incentive to stay in the study.
03:13
World gears up to distribute Covid-19 vaccines as drug makers await medical regulator approvals
Otherwise, trial participants who suspected they were in the placebo group could confirm that hunch by getting tested for antibodies and drop out of the study.
Pfizer representatives also pushed back on the suggestion of a single dose vaccine, echoing comments from CEO Albert Bourla on Tuesday after the positive data were revealed.
“It’s a very big mistake if anyone tries to go with only one dose,” Bourla said in a briefing with reporters. “The truth is we saw some protection from 12 days after the first dose, but clearly the protection is not full.”
People “need to take two doses to be protected”, he added.
Read Politico’s story .
